The circulating transcriptome as a source of biomarkers for melanoma

Carla Solé, Daniela Tramonti, Maike Schramm, Ibai Goicoechea, María Armesto, Luiza I. Hernandez, Lorea Manterola, Marta Fernandez-Mercado, Karmele Mujika, Anna Tuneu, Ane Jaka, Maitena Tellaetxe, Marc R. Friedländer, Xavier P. Estivill, Paolo Piazza, Pablo L. Ortiz-Romero, Mark R. Middleton, Charles H. Lawrie

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The circulating transcriptome is a valuable source of cancer biomarkers, which, with the exception of microRNAs (miRNAs), remains relatively unexplored. To elucidate which RNAs are present in plasma from melanoma patients and which could be used to distinguish cancer patients from healthy individuals, we used next generation sequencing (NGS), and validation was carried out by qPCR and/or ddPCR. We identified 442 different microRNAs in samples, eleven of which were differentially expressed (p < 0.05). Levels of miR-134-5p and miR-320a-3p were significantly down-regulated (p < 0.001) in melanoma samples (n = 96) compared to healthy controls (n = 28). Differentially expressed protein-encoding mRNA 50-fragments were enriched for the angiopoietin, p21-activated kinase (PAK), and EIF2 pathways. Levels of ATM1, AMFR, SOS1, and CD109 gene fragments were up-regulated (p < 0.001) in melanoma samples (n = 144) compared to healthy controls (n = 41) (AUC = 0.825). Over 40% of mapped reads were YRNAs, a class of non-coding RNAs that to date has been little explored. Expression levels of RNY3P1, RNY4P1, and RNY4P25 were significantly higher in patients with stage 0 disease than either healthy controls or more advanced stage disease (p < 0.001). In conclusion, we have identified a number of novel RNA biomarkers, which, most importantly, we validated in multi-center retrospective and prospective cohorts, suggesting potential diagnostic use of these RNA species.

Original languageEnglish
Article number70
JournalCancers
Volume11
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Transcriptome
Melanoma
Biomarkers
RNA
MicroRNAs
Eukaryotic Initiation Factor-2
Angiopoietins
p21-Activated Kinases
Untranslated RNA
Tumor Biomarkers
Area Under Curve
Messenger RNA
Genes
Neoplasms
Proteins

Keywords

  • Biomarker
  • Liquid biopsy
  • Melanoma
  • miRNA
  • mRNA
  • Plasma
  • RNA species
  • YRNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Solé, C., Tramonti, D., Schramm, M., Goicoechea, I., Armesto, M., Hernandez, L. I., ... Lawrie, C. H. (2019). The circulating transcriptome as a source of biomarkers for melanoma. Cancers, 11(1), [70]. https://doi.org/10.3390/cancers11010070

The circulating transcriptome as a source of biomarkers for melanoma. / Solé, Carla; Tramonti, Daniela; Schramm, Maike; Goicoechea, Ibai; Armesto, María; Hernandez, Luiza I.; Manterola, Lorea; Fernandez-Mercado, Marta; Mujika, Karmele; Tuneu, Anna; Jaka, Ane; Tellaetxe, Maitena; Friedländer, Marc R.; Estivill, Xavier P.; Piazza, Paolo; Ortiz-Romero, Pablo L.; Middleton, Mark R.; Lawrie, Charles H.

In: Cancers, Vol. 11, No. 1, 70, 01.01.2019.

Research output: Contribution to journalArticle

Solé, C, Tramonti, D, Schramm, M, Goicoechea, I, Armesto, M, Hernandez, LI, Manterola, L, Fernandez-Mercado, M, Mujika, K, Tuneu, A, Jaka, A, Tellaetxe, M, Friedländer, MR, Estivill, XP, Piazza, P, Ortiz-Romero, PL, Middleton, MR & Lawrie, CH 2019, 'The circulating transcriptome as a source of biomarkers for melanoma', Cancers, vol. 11, no. 1, 70. https://doi.org/10.3390/cancers11010070
Solé C, Tramonti D, Schramm M, Goicoechea I, Armesto M, Hernandez LI et al. The circulating transcriptome as a source of biomarkers for melanoma. Cancers. 2019 Jan 1;11(1). 70. https://doi.org/10.3390/cancers11010070
Solé, Carla ; Tramonti, Daniela ; Schramm, Maike ; Goicoechea, Ibai ; Armesto, María ; Hernandez, Luiza I. ; Manterola, Lorea ; Fernandez-Mercado, Marta ; Mujika, Karmele ; Tuneu, Anna ; Jaka, Ane ; Tellaetxe, Maitena ; Friedländer, Marc R. ; Estivill, Xavier P. ; Piazza, Paolo ; Ortiz-Romero, Pablo L. ; Middleton, Mark R. ; Lawrie, Charles H. / The circulating transcriptome as a source of biomarkers for melanoma. In: Cancers. 2019 ; Vol. 11, No. 1.
@article{370de2727d2b40979ddf2fe91f693f06,
title = "The circulating transcriptome as a source of biomarkers for melanoma",
abstract = "The circulating transcriptome is a valuable source of cancer biomarkers, which, with the exception of microRNAs (miRNAs), remains relatively unexplored. To elucidate which RNAs are present in plasma from melanoma patients and which could be used to distinguish cancer patients from healthy individuals, we used next generation sequencing (NGS), and validation was carried out by qPCR and/or ddPCR. We identified 442 different microRNAs in samples, eleven of which were differentially expressed (p < 0.05). Levels of miR-134-5p and miR-320a-3p were significantly down-regulated (p < 0.001) in melanoma samples (n = 96) compared to healthy controls (n = 28). Differentially expressed protein-encoding mRNA 50-fragments were enriched for the angiopoietin, p21-activated kinase (PAK), and EIF2 pathways. Levels of ATM1, AMFR, SOS1, and CD109 gene fragments were up-regulated (p < 0.001) in melanoma samples (n = 144) compared to healthy controls (n = 41) (AUC = 0.825). Over 40{\%} of mapped reads were YRNAs, a class of non-coding RNAs that to date has been little explored. Expression levels of RNY3P1, RNY4P1, and RNY4P25 were significantly higher in patients with stage 0 disease than either healthy controls or more advanced stage disease (p < 0.001). In conclusion, we have identified a number of novel RNA biomarkers, which, most importantly, we validated in multi-center retrospective and prospective cohorts, suggesting potential diagnostic use of these RNA species.",
keywords = "Biomarker, Liquid biopsy, Melanoma, miRNA, mRNA, Plasma, RNA species, YRNA",
author = "Carla Sol{\'e} and Daniela Tramonti and Maike Schramm and Ibai Goicoechea and Mar{\'i}a Armesto and Hernandez, {Luiza I.} and Lorea Manterola and Marta Fernandez-Mercado and Karmele Mujika and Anna Tuneu and Ane Jaka and Maitena Tellaetxe and Friedl{\"a}nder, {Marc R.} and Estivill, {Xavier P.} and Paolo Piazza and Ortiz-Romero, {Pablo L.} and Middleton, {Mark R.} and Lawrie, {Charles H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/cancers11010070",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - The circulating transcriptome as a source of biomarkers for melanoma

AU - Solé, Carla

AU - Tramonti, Daniela

AU - Schramm, Maike

AU - Goicoechea, Ibai

AU - Armesto, María

AU - Hernandez, Luiza I.

AU - Manterola, Lorea

AU - Fernandez-Mercado, Marta

AU - Mujika, Karmele

AU - Tuneu, Anna

AU - Jaka, Ane

AU - Tellaetxe, Maitena

AU - Friedländer, Marc R.

AU - Estivill, Xavier P.

AU - Piazza, Paolo

AU - Ortiz-Romero, Pablo L.

AU - Middleton, Mark R.

AU - Lawrie, Charles H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The circulating transcriptome is a valuable source of cancer biomarkers, which, with the exception of microRNAs (miRNAs), remains relatively unexplored. To elucidate which RNAs are present in plasma from melanoma patients and which could be used to distinguish cancer patients from healthy individuals, we used next generation sequencing (NGS), and validation was carried out by qPCR and/or ddPCR. We identified 442 different microRNAs in samples, eleven of which were differentially expressed (p < 0.05). Levels of miR-134-5p and miR-320a-3p were significantly down-regulated (p < 0.001) in melanoma samples (n = 96) compared to healthy controls (n = 28). Differentially expressed protein-encoding mRNA 50-fragments were enriched for the angiopoietin, p21-activated kinase (PAK), and EIF2 pathways. Levels of ATM1, AMFR, SOS1, and CD109 gene fragments were up-regulated (p < 0.001) in melanoma samples (n = 144) compared to healthy controls (n = 41) (AUC = 0.825). Over 40% of mapped reads were YRNAs, a class of non-coding RNAs that to date has been little explored. Expression levels of RNY3P1, RNY4P1, and RNY4P25 were significantly higher in patients with stage 0 disease than either healthy controls or more advanced stage disease (p < 0.001). In conclusion, we have identified a number of novel RNA biomarkers, which, most importantly, we validated in multi-center retrospective and prospective cohorts, suggesting potential diagnostic use of these RNA species.

AB - The circulating transcriptome is a valuable source of cancer biomarkers, which, with the exception of microRNAs (miRNAs), remains relatively unexplored. To elucidate which RNAs are present in plasma from melanoma patients and which could be used to distinguish cancer patients from healthy individuals, we used next generation sequencing (NGS), and validation was carried out by qPCR and/or ddPCR. We identified 442 different microRNAs in samples, eleven of which were differentially expressed (p < 0.05). Levels of miR-134-5p and miR-320a-3p were significantly down-regulated (p < 0.001) in melanoma samples (n = 96) compared to healthy controls (n = 28). Differentially expressed protein-encoding mRNA 50-fragments were enriched for the angiopoietin, p21-activated kinase (PAK), and EIF2 pathways. Levels of ATM1, AMFR, SOS1, and CD109 gene fragments were up-regulated (p < 0.001) in melanoma samples (n = 144) compared to healthy controls (n = 41) (AUC = 0.825). Over 40% of mapped reads were YRNAs, a class of non-coding RNAs that to date has been little explored. Expression levels of RNY3P1, RNY4P1, and RNY4P25 were significantly higher in patients with stage 0 disease than either healthy controls or more advanced stage disease (p < 0.001). In conclusion, we have identified a number of novel RNA biomarkers, which, most importantly, we validated in multi-center retrospective and prospective cohorts, suggesting potential diagnostic use of these RNA species.

KW - Biomarker

KW - Liquid biopsy

KW - Melanoma

KW - miRNA

KW - mRNA

KW - Plasma

KW - RNA species

KW - YRNA

UR - http://www.scopus.com/inward/record.url?scp=85060336302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060336302&partnerID=8YFLogxK

U2 - 10.3390/cancers11010070

DO - 10.3390/cancers11010070

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

M1 - 70

ER -